
The “shakers and movers” in the European cannabidiol market in the next two to three years will be big pharma, says Irish synthetic CBD specialist Chanelle McCoy Health. With its purported health benefits, CBD will also need to go the way of OTC drugs, with medicinal claims supported by clinical trials, the firm predicts.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
We are using cookies to give you the best experience on our website.
You can find out more about which cookies we are using or switch them off in settings